Novartis' Pluvicto Shows Promising Results in Expanding Prostate Cancer Treatment

Novartis' therapy for metastatic prostate cancer, Pluvicto, has shown potential benefits as a treatment before chemotherapy, according to Phase 3 data presented at the European Society for Medical Oncology. The trial enrolled patients with metastatic prostate cancer who had previously taken an androgen receptor pathway inhibitor, and the results highlight the effectiveness of radiation-delivering cancer therapies. Novartis' investment in this field is attracting interest from other pharmaceutical companies.